Key result
Extensive LGE mass ≥9.9% linked to more than 3-fold higher SCD or VT risk in cardiac sarcoidosis.
Why the study?
Does extensive late gadolinium enhancement (≥9.9% LV mass or ≥6 segments) predict sudden cardiac death or ventricular tachycardia in patients with cardiac sarcoidosis?
Cohort
Yes
Does extensive late gadolinium enhancement (≥9.9% LV mass or ≥6 segments) predict sudden cardiac death or ventricular tachycardia in patients with cardiac sarcoidosis?
LGE mass ≥9.9% or ≥6 LGE segments on CMR provides specific thresholds to define 'extensive' LGE, identifying cardiac sarcoidosis patients at high risk for sudden cardiac death who may benefit from an ICD.
Answers are grounded in this paper and cite their sources.
May aid SCD risk stratification in cardiac sarcoidosis; leaves open prospective validation before guiding decisions.
BACKGROUND: Cardiac sarcoidosis involves a significant but difficult-to-define risk of sudden cardiac death (SCD). Current guidelines recommend consideration of an implantable cardioverter defibrillator for patients with extensive or significant myocardial late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging. However, extensive/significant LGE is not defined. METHODS: A nationwide cardiac sarcoidosis registry was screened for patients entered before 2020 with cardiac magnetic resonance imaging done before or <3 months after diagnosis. Available studies were re-analyzed for LGE mass as a percentage of left ventricular (LV) mass and the number of LGE-positive LV segments in a 17-segment model. The occurrence of fatal or aborted SCD and ventricular tachycardia (VT) prompting therapy was recorded until the end of 2020 and subjected to cumulative incidence analyses, including competing events (LV assist device implantations, heart transplantations, and fatalities other than SCD). The predictors of SCD/VT were assessed using Fine and Gray modeling and time-dependent receiver operating characteristic analysis. At presentation, 70 patients were free of class I and class IIa implantable cardioverter defibrillator indications unrelated to LGE. Their 5-year rate of SCD/VT was 6.3% (0.0-14.8%) with LGE mass <9.9% versus 21.5% (6.5-36.6%) with higher LGE mass, and 6.9% (0.0-16.3%) with <6 LGE segments versus 20.5% (5.9-35.2%) with ≥6 segments. CONCLUSIONS: In cardiac sarcoidosis, myocardial LGE making up ≥9.9% of LV mass or affecting ≥6 LV segments may suggest prognostically significant LV involvement and a high risk of SCD. However, prospective validation of the thresholds is needed.
No takes yet. Share an insight, caveat, or question.
Pöyhönen et al. (2024) conducted a cohort in Cardiac sarcoidosis. Myocardial late gadolinium enhancement (LGE) mass ≥9.9% or ≥6 LV segments vs. LGE mass <9.9% or <6 LV segments was evaluated on Fatal or aborted sudden cardiac death (SCD) and ventricular tachycardia (VT) prompting therapy (p=<0.001). In cardiac sarcoidosis, myocardial LGE mass ≥9.9% was associated with a higher 5-year rate of sudden cardiac death or ventricular tachycardia compared to LGE mass <9.9%.
Synapse has enriched 10 related papers. Consider them for comparative context: